The largest-ever clinical trial of psilocybin — the psychedelic compound found in "magic mushrooms" — is set to begin by the end of December.
It's the first time a clinical trial of the hallucinogen has reached Phase 3, one of the last steps necessary before an experimental drug can go to the Food and Drug Administration for possible regulatory approval.
The research will look at whether the drug can effectively treat depression when other therapies have failed.
For more on this story, go to NBC News.
Feeling out of the loop? We'll catch you up on the Chicago news you need to know. Sign up for the weekly Chicago Catch-Up newsletter here.